Center, S-752 23 Uppsala and 2Department of Pathology, University Hospital, S-751 85 Uppsala, Sweden. Platelet-derived growth factor (PDGF), is a dimer of two polypeptide chains, A and B. Examples have been found of A homodimers (e.g. a factor secreted by a human osteosarcoma cell line), B homodimers (e.g. the transforming product of simian sarcoma virus) and AB heterodimers (e.g. PDGF purified from human platelets 
normal epithelial cells. Using cultured skin keratinocytes as a model system for normal epithelial cells, the production of and response to TGFa and TGFf has been examined along with potential mechanisms of growth inhibition by TGFfl.
The keratinocytes are stimulated to proliferate by EGF and TGFa. TGFa is produced by adult and neonatal skin keratinocytes, and this production is autoregulated. TGF#, on the other hand, is a potent inhibitor of keratinocyte proliferation. The mechanism of growth inhibition by TGFfl appears to involve selective inhibition of expression of growth factor inducible genes necessary for cell proliferation.
The keratinocytes also synthesize and release TGF#, but in a latent form; the major regulatory step Transforming growth factor-beta (TGF-beta) is a 25,000 dalton disulfide-linked homodimeric peptide found principally in platelets and bone, suggesting a role in tissue repair and remodeling. It controls a broad spectrum of biological responses including cell growth, cell differentiation, other cell functions (for a review, see Sporn et al., J. Cell Biol., 105, 1039 , 1987 . TGF-beta is secreted by and acts on many of the cells common to the stromal elements of a tumor and the granulation tissue of a healing wound, namely inflammatory cells, endothelial cells, and fibroblasts. Thus at femtomolar concentrations, TGF-beta is chemotactic for both macrophages and fibroblasts, while at higher concentrations, it activates macrophages to secrete mitogens such as IL-1 and fibroblasts to secrete connective tissue proteins such proteoglycans, fibronectin, and types I, III, and V collagen. The accumulation of matrix proteins is further augmented by a second TGF-beta-dependent mechanism in which the peptide decreases cellular secretion of matrix-degrading proteases and increases synthesis of protease inhibitors. The acute release of TGF-beta from platelets which initiates the healing response is replaced in tumorigenic development by continuous aberrant secretion of the peptide by the tumour cells. It is the ability of the tumour to perpetuate the normally self-limiting healing response that distinguishes these two processes. The central role of TGF-beta in both processes provides the mechanistic link between them.
Peptides of the bombesin family: Receptors and mitogenic actions E. Rozengurt, I. Zachary, J. Sinnett-Smith, E. Nanberg, P.J. Woll & J. Millar Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn Fields, London WC2A 3PX, UK.
Regulatory peptides which act in an autocrine or paracrine fashion on adjacent cells are increasingly implicated in the control of cell proliferation. The amphibian tetradecapeptide bombesin and mammalian peptides structurally related to bombesin including gastrin-releasing peptide (GRP) are potent mitogens for Swiss 3T3 cells. These peptides bind to high-affinity cell-surface receptors which are distinct from those of other mitogens for these cells. A surface protein in Swiss 3T3 cells with apparent Mr 75000-85000 has been identified by chemical cross-linking as a putative component for the bombesin/GRP receptor. The affinity labelled protein binds to wheat germ lectin-sepharose columns from which it can be eluted by N-acetyl-D-glucosamine. Receptor bound 1251-GRP is internalised and extensively degraded by these cells. However in contrast to other growth factors, peptides of the bombesin family do not cause down-regulation of their specific cell-surface receptors. Following binding the peptides elicit a complex array of early biological responses including: (a) phosphorylation of the 80K cellular protein, which reflects the activation of protein kinase C in intact 3T3 cells; (b) phosphoinositide breakdown and mobilisation of Ca2 + from an intracellular store, which leads to a transient increase in the concentration of cytosolic Ca2+ and Ca2+ efflux; (c) stimulation of activity of the Na+/H+ antiport; (d) transmodulation of EGF-receptor affinity; (e) enhancement of cAMP accumulation; and (f) increase in the expression of the cellular oncogenes c-fos and c-myc. The peptides of the bombesin family not only provide a novel and valuable model for the elucidation of the signal transduction pathways underlying cellular proliferation but also play a role as autocrine growth factors for human small cell lung cancer cells. (PDGF) . Growth factor function may be dependent upon cellular interactions and may result in the release of substances by cells that lead to a cascade of events culminating in cellular responses ranging from chemotaxis and increased cell contractility to DNA synthesis and cell replication. Tumour growth may result from autocrine stimulation by growth factors such as PDGF, whereas factors such as PDGF may also act in a paracrine fashion to induce fibroproliferative responses such as desmoplasia, which often accompanies different neoplasms. Connective tissue proliferation can also occur as a result of growth factor release from macrophages involved in the process of inflammation and wound repair. Thus these factors may play critical roles in cell proliferation, which is the hallmark of diseases that include atherosclerosis, rheumatoid arthritis, pulmonary fibrosis, and neoplasia.
The 8th Gordon Hamilton-Fairley Memorial Lecture
The interleukins: Lymphocytic growth and differentiation factors C.S. Henney Immunex Corp., Seattle, WA 98101, USA.
The interleukins are a group of protein hormones produced by lymphocytes and macrophages which control the growth, differentiation and activation of cells of the immune system. The interleukin 'family' is grouped only by its biological effects; there is no interleukin gene 'family', nor do the proteins encoded by interleukin genes share structural homology.
To date, five interleukin genes have been cloned, and their products, interleukins 1 through 5, have been characterized chemically and biologically. One of these proteins, interleukin-2, has been assessed clinically as an immunorestorative and immunopotentiating agent; clinical testing of interleukins 1, 3 and 4 will begin within the next year.
The interrelated biological effects of the interleukins will be discussed with a particular focus on the clinical potential of these proteins in the treatment of immune dysfunction. The first human tumour derived protein with in vivo angiogenic activity to be obtained in pure form has been isolated from serum-free supernatants of an established human adenocarcinoma cell line (HT-29) and named angiogenin. Biological activity of angiogenin was monitored throughout purification by using the chick embryo chorioallantoic membrane assay. It displays activity in this system with as little as 35 fmol per egg, and only 3.5 pmol is required to induce extensive blood vessel growth in the rabbit cornea. The amino acid sequence and disulfide bond pairing of human tumour derived angiogenin have been determined by conventional sequencing techniques adapted and applied to nanomole and subnanomole levels of material. Angiogenin obtained from such conditioned media is a single-chain protein consisting of 123 amino acids (I.P. > 9.5) and molecular weight -14,400.
The sequence is homologous to that of the pancreatic ribonucleases with 35% identity and many additional residues are replaced conservatively. Similarities are especially apparent around the major active-site residues His-12, Lys-41, and His-I 19 of ribonuclease which are conserved as are three of the four disulfide bonds.
This unexpected homology to ribonuclease A suggests novel approaches to the investigation of the biological process of angiogenesis and may be relevant to the evolution of organogenic molecules and their physiological implications. The search for mechanisms which explain the molecular basis of signals which generate the abnormal growth properties of transformed cells in vitro and cancer cells in vivo has in the last few years, focused on pathways involved in growth factor signal transduction. Through the ability to characterise, the structure and function of growth factors and their receptors linked to progress made in understanding oncogenes, tumour promoters and cell physiology, major conceptual advances have occurred. Thus, through abnormal production of a growth factor what may be an intra or extracellular autocrine control loop can be established. Subversion can occur by activation of a cellular gene or through generation of an oncogene. An alternative mechanism may be to obviate the need for the factor, for example by generation of an altered receptor which may mimic the signal of ligand stimulated receptor or through the action of a tumour promoter mimic an activator and activate second messenger generation. In some cases, an intracellular signal may be generated to bypass the entire receptor system.
Abstracts of proffered papers
The prognostic value of immunohistochemical assessment of c-erbB-2 amplification in human breast tumours There is increasing interest in the role of the c-erbB-2 oncogene in the pathogenesis of human breast cancer. An immunohistochemical study has been carried out using a polyclonal antibody (21N) raised to a peptide consisting of residues 1243-1255 of the open reading frame of the c-erbB-2 molecule. (Gullick et al., Int. J. Cancer, 40, 246, 1987) .
Formalin-fixed paraffin embedded sections of 150 primary breast tumours from patients followed up for a period of 10-12 years, were studied. Staining was carried out with the primary antibody at dilutions ranging from 1/20 to 1/400, using the avidin-biotin technique. Specificity was confirmed by the elimination of staining following pre-incubation of the primary antibody with the immunising peptide. Due to heterogeneity of staining, several scoring systems were devised, reflecting patterns of staining intensity and distribution. Using each system the staining for the tumours was graded as: (a) The presence or absence of epidermal growth factor receptor (EGF-R), and oestrogen receptor (E-R) was determined in 156 patients. The amount of EGF extractable. from the tissue was measured when sufficient tissue permitted. E-R was measured using the dextran coated charcoal seven point competition assay which is used routinely in our EORTC studies. EGF-R was detected using a 2 point radioreceptor assay and EGF was measured by RIA with an 'in house' rabbit polyclonal anti-EGF antibody.
The Table demonstrates the relationship between EGF-R and E-R and EGF. The x2 test indicated no significant correlation between any of the parameters. These findings, however, differ from those of Sainsbury et al. (Lancet, i, 364, 1985) . Res., 46, 285, 1986) , also against the cytoplasmic domain of EGF-R. In this series 9/27 primary bronchial biopsies were positive with both antibodies, while a further 6 were positive with EGF-RF4 alone; 3/6 secondary deposits were positive with both. Twenty-three patients with known or suspected brain tumours were scanned using 123-iodine labelled monoclonal antibodies against epidermal growth factor receptor (EGFR1) and placental alkaline phosphatase (H17E2). Ten patients were also imaged using a non-specific control antibody (11.4.1) of the same immunoglobulin subclass. Successful localisation was achieved in 19/23 patients. The specificity of targetting was confirmed by comparing imaging using specific and non-specific antibodies and examining biopsies after dual antibody administration.
Seven pateints with recurrent grade III or grade IV glioma who showed good localisation of radiolabelled antibody were treated with 40-140mCi of 131-iodine labelled antibody delivered to the tumour area by infusion into the internal carotid artery. Six patients showed clinical improvement lasting from 3 months to 2 years. One patient continues in remission (2 years after therapy), but 5/6 patients who responded initially, relapsed 6-12 months post therapy and died. No Immunol., 133, 3096, 1984 The distribution and intensity of epidermal growth factor (EGF) receptor expression varies between patients with oral squamous cell carcinoma (SCC) although there appears to be no significant correlation between the level of receptor expression and tumour behaviour. EGF is only one of several polypeptide growth factors involved in normal cell proliferation. Another is transforming growth factor-alpha (TGF-a) which is structurally related to EGF and also binds to the EGFR.
We have demonstrated production of varying amounts of TGF-as by oral SCC using Northern blotting and radioimmunoassay. Tumours which express EGFR may therefore have enhanced proliferation in response to autocrine or paracrine production of TGF-a.
TGF-x mRNA and protein were also present in cultured human keratinocytes. There is increased secretion of TGF-x by these cells in response to 10ngml-' EGF. Antibodies raised in sheep to mouse EGF were used to test if host derived EGF is required for the progressive growth in vivo of low numbers of carcinoma cells which contain TGFa activity but do not make mEGF. ELISA showed that the antibody cross-reacted weakly with hEGF and TGFa but did not inhibit hEGF or TGFa induced mitogenesis. However the IgG inhibited the mintogenic activity of mEGF in a manner that depended both on the dose of IgG and the amount of mEGF used.
In vivo anti-tumour activity of the antibody was tested against a transplanted mammary carcinoma which grows from 5 x 103 cells i.p. 2.5 mg of IgG was given i.p. three times a week. In the first experiment the mice were killed-at 29 days: 5/5 untreated mice had large omental tumours while in the treated group 2/5 were tumour free and 3/5 had small tumours. In the second experiment the mice were followed for up to 3 months: in the untreated group Urogastrone (hEGF) in urine was measured by a specific two-site ELISA which does not detect mEGF or TGFa. More than 99.99% of the hEGF in urine could be removed by binding to a monoclonal antibody. Absorbed urines were analysed for growth factors other than hEGF by competitive binding to EGF receptors and by mitogenic activity measured by induction of DNA synthesis in density-inhibited foreskin fibroblasts under conditions where EGF, TGFa and PDGF were active but added insulin or transferrin were not. After absorption, urinary hEGF was eluted from antibody and after separation by FPLC (anion-exchange) immuneand receptor-binding activity was found in several fractions, none of which coincided with the peak from plasmid derived hEGF produced in E. coli.
The hEGF/creatinine ratio in the urine of untreated patients with colon and breast cancers (and a small number with bladder cancer and hypernephroma) was elevated but within the normal range. The chromatographic profile of hEGF from the urine of cancer patients could not be distinguished from that of normals. Following hEGF absorption, no receptor binding or mitogenic activity could be detected in whole urine.
As synthetic human TGFoa is readily separable by FPLC from the hEGF components, urine free of hEGF was separated by FPLC and the mitogenic activity of the fractions measured. PDGF and basic fibroblast growth factor does not bind to the anionic column and would not be detected. The expression of cytochrome P-450 and glutathione-Stransferase (GST) isozymes has been analysed in a number of breast tumour samples. Immunoblotting shows that all breast tumours analysed contained a cytochrome P-450 form associated with the P-450 C2C locus. Isozymes within this locus appear to be invovled in steroid hydroxylations which may relate to hormone homeostasis with the tumour and the metabolism of drugs such as tamoxifen. The metabolism of 7-ethoxyresorufin (a marker substrate for P-450 C2C) could also be detected in these tumours. Other cytochrome P-450s analysed within the P-450 C2A, P-450 C2B and P-450 Cl loci were not detected in these samples. All breast tumour samples analysed expressed high levels of the acidic (A) GST (Carney et al., Cancer Res., 47, 821, 1987) . We have shown synthesis of insulin-like growth factor-I (IGF-I) by most SCLC and non-SCLC tissues and cell lines. We examined the effects on human lung cancer cell lines of an inhibitor of peptide secretion. The long-acting octapeptide somatostatin analogue sandostatin was tested on 3 SCLC and 3 non-SCLC lines. The assay system measured 3H-thymidine uptake by cell suspensions in unsupplemented RPMI medium. Two of the 3 SCLC cell lines synthesise and secrete detectable levels of bombesin and IGF-I. However sandostatin 0.0O1-lOOOngml-' (10-12-106M) had no significant effect on DNA synthesis by these lines. None of the 3 non-SCLC lines produce bombesin, but IGF-I is detectable in 2 (NCI-H125, adenocarcinoma; NCI-H226, squamous). NCI-H226 showed inhibition of 3H-thymidine uptake to 68+6% of control levels (P<0.01) in response to sandostatin 1000ngml-. We also saw an effect in one of the 2 adenocarcinoma lines, NCI-H23. There was significant inhibition (89 ± 0.5%, P <0.05) even at the lowest drug concentration; the effect was maximal at 1000ngml'1 (79+4%, P<0.01). In the presence of 10% serum we were unable to show activity in any line. Thus we have demonstrated only modest effects in 2 of 3 non-SCLC but 0 of 3 SCLC cell lines. There was no correlation between response and synthesis/secretion of bombesin or IGF-I. Growth factor secretion may not be a prerequisite for receptor binding and activation. We plan to assess the effect of sandostatin on serial peptide secretion, and to alter drug schedules to maximise growth inhibition. We have carried out a retrospective analysis of 164 patients (pts) with recurrent melanoma seen at the Royal Marsden Hospital between 1976-1986 who had received no previous chemotherapy. They received one of four chemotherapy regimens: Vindesine (VDN) 3mg m -2 weekly (80 pts), melphalan (HDM) 200 mg m -2 with autologous bone marrow transplantation (ABMT) (34 pts), BCNU (HDBCNU) 800 mg m-2 with ABMT (9 pts) and BOLD regimen (bleomycin, vincristine, CCNU, DTIC) (41 pts). The groups were similar in their age, sex and clinical characteristics. The indications for chemotherapy were progressive disease or uncontrolled symptoms, usually pain. The response to treatment was evaluated using the WHO criteria. The response rates (CR + PR) for the four treatment schedules were: VDN 2.5%, HDM 20.6%, HDBCNU 44.4% and BOLD 24.4%. Although the response rates for HDM, HDBCNU and BOLD were significantly higher (P <0.005) than that for VDN, there was no evidence of prolonged survival with any of the chemotherapy regimens and the choice of treatment was not a significant predictor of survival on multivariate analysis, although responders lived longer than non-responders as usual. Toxicity was predictably greatest with high dose and combination chemotherapies. The results are disappointing. High dose and combination chemotherapy can improve response rates but there are few complete remissions and the increase in partial remissions does not seem to improve survival in this disease. It seems probable that only a treatment which produces complete remissions is likely to do this. The levels of mRNAs for platelet-derived growth factor (PDGF) A and B chains and insulin-like growth factor II (IGF-II) known to be secreted by some human breast cancer cell lines, and to stimulate proliferation of mesenchymal cells in vitro, were examined in 51 malignant and 19 nonmalignant human breast biopsies by northern and dot blot analysis using human cDNA probes. PDGF-A and B chain transcripts were found in all normal and benign tissue examined. All tumours studied contained PDGF-A transcripts (38/38) and 33/37 (89%) possessed detectable mRNA for the PDGF-B chain. Variations in the levels of A and B chain transcripts were observed in 26 malignant and 8 non-malignant breast samples suggesting a lack of coordinated expression of these factors. However, the levels of these transcripts found in lymph node metastases from 5 patients were similar to those found in their respective primary tumours. PDGF-A and B chain expression was also found to be unrelated to oestrogen receptor protein levels. Northern analysis showed a single 4 kb PDGF-B chain transcript and three bands of 2.9, 2.4 and 1.8 kb for PDGF-A. IGF-II transcripts of sizes 6 and 4.8 kb were abundant in all normal and benign tissues (15/15) and were present, but at much lower levels in 11/21 (52%) of carcinomas. The level of stromal invasion was assessed on frozen sections from 30 carcinomas and showed no relationship to the level of A and/or B chain transcripts. The association of IGF-II message with normal and benign tissue may reflect a role for this growth factor in promoting the proliferation of stromal elements. Alternatively stromal cells may themselves secrete this growth factor. Studies involving in situ hybridisation of benign and malignant tissue sections may help to resolve these questions. Mammalian palatogenesis involves the differentiation of epithelia from 3 regions of the palate (oral, nasal and medial edge), into specific phenotypes. This differentiation is directed by the underlying mesenchyme (Ferguson & Honig, Curr. Top. Develop. Biol., 19, 137, 1984) . Immunocytochemical and proliferative studies on mouse embryonic palatal mesenchyme (MEPM) cells were undertaken to elucidate molecular controls of mesenchyme signalling. Extracellular matrix (ECM) deposition and proliferation were compared when cells were cultured on various substrata (on plastic, on collagen gel and in collagen gel), in response to DMEM/F12 medium supplemented with donor calf serum with or without platelet derived growth factor (PDGF) and transforming growth factor beta (TGF-B). PDGF elicited substrate specific mitogenic responses; stimulation on plastic, no effect on collagen and inhibition within collagen gel matrices. TGF-B exerted inhibition of cell growth irrespective of culture substratum. Immunocytochemical localisation of collagen types I, III, IV, V, IX, fibronectin, laminin, tenascin and heparan sulphate proteoglycan when MEPM cells were cultured on glass or collagen film substrata in the presence of absence of PDGF and TGF-B indicated that with TGF-B present collagen types III, IV, V, fibronectin and laminin were qualitatively more abundant. PDGF had no apparent effect with the exception of an increase in type III collagen production. These results implicate regulatory roles for both PDGF and TGF-B during palate development. TGFf is a potent non-toxic inhibitor of mitogen-induced DNA synthesis in primary cultures of adult rat hepatocytes (Cancer Res., 46, 2330 , 1986 . Since TGFfl gene expression occurs in rat liver, we investigated whether a variety of human and rat hepatomas differed from normal hepatocytes in response to the inhibitory actions of TGF/. Hepatocytes or hepatoma cell lines were culture in serum-free medium for 24h with TGFB 0-10ngmlP-. The medium was then changed to fresh medium containing growth factors (hepatocytes) or foetal calf serum (hepatomas) without TGF,B. DNA synthesis was assessed 72-96 h later (normal hepatocytes) or growth curves were measured over the subsequent days (hepatomas). Normal human foetal hepatocytes were similar to rat hepatocytes in the dose responsiveness to the inhibitory actions of TGFP with an ID50 of 0.5 ngml -'. Growth curves on rat hepatomas H-4-II-E, RH7777 and HTC, and human hepatomas HEP G2, PRC/PRF/5, HEP 3B. HuH-7 and SK-HEP-1 showed no inhibition of growth at any of the tested doses except for HEP 3B and HuH-7 which showed 50% inhibition at lOngml-PTGFf. The binding of 125I-TGFfl was measured on all hepatocyte cell lines. The hepatomas had between 150-800% of the binding of normal rat hepatocytes, measured over 4h at 4°C. Affinity cross-linking gels showed at least 4molwt species of TGF10 receptor. The hepatoma cell lines produced a factor(s) in their medium which caused a > 10-fold increase in DNA synthesis when tested on normal rat hepatocytes and completely antagonized any inhibitory effects of TGF#. This endogenously-secreted growth stimulant may be important in the resistance of hepatomas to the growth inhibitory action of TGF/. Transforming growth factor f (TGFJ) is a potent reversible inhibitor of DNA synthesis in adult rat hepatocytes in vitro.
Our previous work has shown that TGFP inhibits DNA synthesis in hepatocytes isolated from normal liver and from regenerating liver 18 h following partial hepatectomy with equal potency (Strain et al., Biochem. Biophys. Res. Com., 45, 436, 1987) . In the present study, the response of hepatocytes from 3h, 6h and 12h regenerating liver was determined. Hepatocytes were isolated by collagenase perfusion and were maintained in serum-free William's E medium for up to 5 days. Medium with or without growth factors was replenished daily and [3H]-thymidine added for the final 24h of culture.
TGFP inhibited DNA synthesis uniformly in hepatocytes from normal liver and from 3 h, 6 h and 12 h regenerating liver in the absence of epidermal growth factor (EGF). However, cells from 3 h and to a lesser extent from 6 h regenerating liver maintained in the presence of 0.85 nM EGF for 72 h were less sensitive to the growth inhibitory action of TGFf.
[3H]-thymidine incorporation was inhibited at 20pM TGF,B by only 7% and 33% in hepatocytes from 3 h and 6 h regenerating liver respectively compared with 70% in normal hepatocytes. No change in sensitivity was observed in cells from rats following sham hepatectomy. Within a further 24-48 h, TGFfi inhibited DNA synthesis by a similar degree in hepatocytes from 3 h regenerating liver in the presence or absence of EGF. These data are compatible with the hypothesis that TGF,B plays a role as a paracrine growth regulator in adult rat liver. Thus, following partial hepatectomy a transient decrease in sensitivity of hepatocytes to the growth inhibitory action of TGF,B would result in release of cells from growth restraint. In this study the effect of cx-IF (Kirby-Warrick) on the rate of proliferation, phenotypic expression of ER and cellular levels of TGF-f mRNA was determined for ER+ve breast cancer cells . Continuous exposure of exponentially growing cells to a-IF (500 IU ml-') significantly increased cell doubling time from 23.2 to 42.5h (P<0.05). Approximately 12h after initial treatment with ot-IF, ER levels had fallen to 15-20% of control values (P<0.05) and stayed at this reduced level in the presence of a-IF. RNA was phenol extracted from exponentially growing cells and TGF-# mRNA levels were assessed by standard dot hybridisation with a cDNA probe specific for TGF-,B. 24h following a-IF treatment, TGF-f mRNA had risen by approximately 5-10 fold relative to control and was maintained at this elevated level until a-IF was removed from culture medium.
Preliminary studies indicate that for TGF-# has an antiproliferative effect on ZR-75 cells and it is possible that the cytostatic effect of x-IF is mediated by variation in phenotypic expression of ER and TGF-/3.
The trophic effects of gastrin on the human gastric cell line, MKN45 in vitro and in vivo Selected human small cell lung carcinoma (SCLC) cell lines contain high levels of neurotensin but fail to express specific cell surface neurotensin binding sites (Goedert et al., Br. J. Cancer, 50, 179, 1984) , suggesting that unlike bombesin, this peptide has no autocrine mode of action in these cells. To investigate this possibility, neurotensin was added to SCLC cell lines growing in vitro in HITES medium, at concentrations ranging from 50nm to 5pM. Cells were counted at intervals during a 7-10 day period. Among the 8 SCLC cell lines (6 'classic'; 2 'variant') neurotensin exhibited dosedependent anti-proliferative activity. This effect was also seen in a large cell lung carcinoma cell line and in a breast carcinoma cell line. Experiments carried out in RPM 1 containing 10% fetal calf serum showed a significant but reduced anti-proliferative effect for neurotensin. Structureactivity studies indicated the importance of COOH-terminal structures as determinants of specific neurotensin binding and biologic action. To date partial NH2 terminal sequences including NT1-10 have no known physiological effects. However, when NH2-and COOH-terminal fragments were assessed for anti-proliferative effects on SCLC cell lines, both were found to be of similar potency as the complete peptide at equimolar doses. These observations, together with the lack of detectable neurotensin binding sites on several of the SCLC cell lines used in this study, indicate that the growth inhibitory action of neurotensin is not mediated via interaction with specific, high affinity neurotensin receptors.
A potent bombesin antagonist [DArg', DPhe5, DTrp7'9, Leull] Folkman, NIPS, 1, 199, 1986) . We report here that interleukin-l (IL-1) may also be an angiogenic factor. The method (Andrade et al., Br. J. Exp. Path., 68, 755, 1987 ) is based on subcutaneous implantation of sterile polyester sponges in rats and subsequent measurement of blood flow in the implants as they become vascularised. Saline, vehicle control or different concentrations of IL-1 in lOO1 uI was injected into the sponge via an attached cannula. Histological studies of implants removed at fixed time intervals confirmed that the sponges were gradually infiltrated by host blood vessels. The blood flow in an implant was measured in terms of 133Xe-saline clearance 6min after the radioisotope was injected into the sponge via the cannula. Under standard conditions, the 133Xe clearance from control sponges 16 days postimplantation approached the clearance obtained in normal skin. However, 5ng of porcine IL-lx (Saklatvala et al., J. Exp. Med., 162, 1208 , 1985 caused accelerated angiogenesis 10+1 days post-implantation. Higher doses (20, 50ng) of IL-1 were also effective, though there were no significant differences between the three test groups. Further work to assess the relative contribution of IL-1, FGF, TGF and other growth factors in this model of angiogenesis is underway. The angiogenic activities of a number of purified growth factors have been determined using a novel in vivo assay, first described by Andrade et al. (Br. J. Exp. Path., 68, 755, 1987) . A sterile polyether polyurethane sponge disc (1.25 cm x 0.6 cm) with an attached polyethylene cannula (1 cm long) was implanted into the dorsal subcutaneous tissues of groups of young adult Wistar rats. Since clearance of radiolabelled xenon can be used to measure blood flow (Sjersen, Circ. Res., 25, 215, 1969; Fan & Lewis, Br. J. Pharmacol., 74, 964, 1981) progressive vascularisation of the sponge was assessed by injecting 10p1 of Xenon133 solution (370 MBq in 3 ml specific activity) into the cannula then at various times monitoring clearance rates using a collimated y-detector placed directly over the implanted sponge. Standard clearance curves from controls (PBS only) were compared with those from rats receiving (1) TGF-a; 3 pg on day 7 after implantation, (2) IL-lIa; 4.8 pg/day on days 7, 8, 9 and 10 or (3) TNF-oc; 5 pg/day on days 7, 8, 9 and 10.
At IL-1 is a radioprotector in mice (Neta et al., J. Immunol., 136, 2483 , 1986 . We have measured its effect on haemopoietic recovery, as measured by spleen colony forming units (CFU-S), in relation to total body irradiation (TBI) and chemotherapy. IL-1 (2000U i.p. 20h before TBI or drug) did not enhance CFU-S recovery after carboplatin, busulphan or melphalan and indeed appeared to exacerbate gut toxicity of melphalan, as measured by crypt survival. However IL-1 at this dose did increase CFU-S post TBI (assessed on day 7 post TBI) between 6 and 14 fold.
Synergistic action with other biologicals may be important. GM-CSF (100pgkg-1 i.p. bd for 6 days starting 48 h before TBI), increased CFU-S recovery 12 fold. A combination of IL-1 and GM-CSF, administered as above, resulted in an enhanced increase of CFU-S at 26 fold. In vitro, using human bone marrow, the number of granulocyte macrophage colonies (GM-CFUc) increased as a function of GM-CSF concentration up to a maximal value which varied between patients. IL-1 enhanced the response of GM-CFUc to GM-CSF (P <0.06): this response was dependent on the dose of IL-1. IL-1 alone did not stimulate GM-CFUc. The best results were seen with GM-CSF lOOngml-l and IL-1 320Uml-1.
We conclude that biological agents should be used in combination and may have a role in enhancing haemopoietic recovery after irradiation. Neutropenia as a consequence of chemotherapy is probably the most important factor responsible for increasing susceptibility to infection in patients and hence one of the main reasons for hospital admission during treatment. RhG-CSF is a recombinant protein, similar to the naturally occurring substance which increases the production of neutrophils in man. In our study all patients have the diagnosis of small cell lung cancer and are treated by a combination of adriamycin 50mgm-2 i.v. bolus, ifosfamide 5gmm-2 +mesna i.v. infusion (both on day 1 of each cycle) and VP16 120mgm-' i.v. on days 1, 2 and 3. In phase I study (prior to chemotherapy) 7 patients have so far been studied for toxicity and effect on bone marrow (both in vitro and in vivo parameters) of rhG-CSF administered by continuous i.v. infusion at three different doses (1, 5 and 10ygkg-'day-'). In the phase II study the same patients are given rhG-CSF (as before) on alternate cycles of chemotherapy, acting as their own control. No toxicities were observed during the phase I part of the study -in all 7 patients the number of peripheral neutrophils increased in a dose-dependent manner and granulocyte-function tests proved them to be normally-functioning granulocytes.
During the phase II part of the study the period of neutropenia was considerably reduced while on G-CSF following chemotherapy (with a return to normal or above normal peripheral neutrophil counts within two weeks after day 1). We have developed an ELISA assay that detects a labile tumour necrosis factor-a, TNF-a, like activity in freshly obtained serum from cancer patients. 50% of 226 samples from cancer patients with active disease were positive as compared to 3% of 32 samples from normal individuals and 18% of 39 samples from cancer patients with no evidence of disease (P<0.0003). The activity can be absorbed from serum by beads coated with monoclonal antibody to TNF-a. Serum samples from patients with ovarian and oat cell carcinoma were more frequently positive (69% and 63%) than those patients with lymphoma (26% positive). When RNA preparations from peripheral blood mononuclear cells, PBMC, or solid tumours, were probed with TNF-a cDNA, we found evidence for TNF-a mRNA in 8 of 11 samples from cancer patients but only 1 of 8 normal individuals. In addition, TNF-cx mRNA was detected in 2 of 6 colorectal tumours. TNF-cx may be involved in a host response to cancer, or its production could be part of the process of tumorigenesis. This cytokine could contribute to the symptoms and evolution of some cancers.
The therapeutic potential of TNF-ac and its combination with IFN-y We have studied the antitumour activity of human tumour necrosis factor-a, TNF-cx, and human interferon-y, in human tumour xenograft models. When a range of xenografted cancers (breast, bowel, ovarian) were studied, TNF-a was effective when given locally (intraperitoneally, i.p. to i.p. tumours, intratumourally, i.t. to subcutaneous s.c. tumours) but not systemically. Its combination with IFN-y was additive or synergistic in the i.p. but not s.c. tumours, resulting in a 3 fold or more increase in lifespan of mice.
The human IFN-y had no measurable effect on the nude mouse host, but the human TNF-c caused distinctive changes in host cell populations. Within hours of the first injection of TNF-a there was a prominent increase in polymorphs i.p. and in the blood. This declined after several days even with repeated injections but after 14-21 days of daily therapy a pronounced lymphocytosis developed in TNF-x treated mice. Solid i.p. tumours treated with TNF-ci showed a marked inflammatory infiltrate and by day 3, central necrosis. Tumour cells became replaced with collagenous material. These changes in solid tumours were more pronounced in the tumour lines that responded to TNF-a with increased mouse survival time. 
